| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2024 ( Subtotal = $57,346,977 ) (Continued on the next page) |
| | 2024 | 2024 | THE UNIVERISTY OF TEXAS MD ANDERSON CANCER CENTER, A COMPONENT OF THE UNIVERISTY OF TEXAS SYSTEM | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | K08CA263298 | Skin Cancer Risks and Risk Prediction in Patients with Actinic Keratosis | 000 | 3 | NIH | 3/4/2024 | $260,582 |
| | 2024 | 2024 | UNIVERSITY OF TEXAS M. D. ANDERSON CANCER CENTER, THE | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4000 | HARRIS | USA | R01CA260661 | Metabolic basis of ARID1A-mutated ovarian cancer | 000 | 3 | NIH | 11/15/2023 | $440,741 |
| | 2024 | 2024 | THE UNIVERISTY OF TEXAS MD ANDERSON CANCER CENTER, A COMPONENT OF THE UNIVERISTY OF TEXAS SYSTEM | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01DE030875 | Functional roles of GOF TP53 mutations in metastasis and immunosuppression of head and neck cancers | 000 | 3 | NIH | 2/13/2024 | $500,532 |
| | 2024 | 2024 | THE UNIVERISTY OF TEXAS MD ANDERSON CANCER CENTER, A COMPONENT OF THE UNIVERISTY OF TEXAS SYSTEM | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01MD017999 | Health equity in fertility specialty care among cancer survivors | 001 | 2 | NIH | 12/9/2023 | $615,106 |
| | 2024 | 2024 | THE UNIVERISTY OF TEXAS MD ANDERSON CANCER CENTER, A COMPONENT OF THE UNIVERISTY OF TEXAS SYSTEM | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01HL159960 | Biodegradable Radiopaque Polymeric Scaffolds Loaded with Mesenchymal Stem Cells for Image-Guided Arteriovenous Fistula Maturation and Long-Term Patency | 000 | 3 | NIH | 3/12/2024 | $405,440 |
| | 2024 | 2024 | THE UNIVERISTY OF TEXAS MD ANDERSON CANCER CENTER, A COMPONENT OF THE UNIVERISTY OF TEXAS SYSTEM | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01CA261750 | Personalized Risk Prediction to Reduce Cardiovascular Disease in Childhood Cancer Survivors | 000 | 3 | NIH | 4/15/2024 | $769,340 |
| | 2024 | 2024 | THE UNIVERISTY OF TEXAS MD ANDERSON CANCER CENTER, A COMPONENT OF THE UNIVERISTY OF TEXAS SYSTEM | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01NS122052 | Analyzing Adhesion and Signaling Functions for PTPN12 in Invasive Glioma Cells | 000 | 3 | NIH | 12/28/2023 | $360,856 |
| | 2024 | 2024 | THE UNIVERISTY OF TEXAS MD ANDERSON CANCER CENTER, A COMPONENT OF THE UNIVERISTY OF TEXAS SYSTEM | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01HL158796 | New data science approaches to visualize and understand the impact of the microbiome on risk of graft-versus-host disease | 000 | 3 | NIH | 2/2/2024 | $243,000 |
| | 2024 | 2024 | UNIVERSITY OF TEXAS M. D. ANDERSON CANCER CENTER, THE | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4000 | HARRIS | USA | R01NS122143 | Analyzing the Endothelial Cell-Expressed Prion Gene Prnd in Vascular Development | 000 | 3 | NIH | 11/28/2023 | $360,856 |
| | 2024 | 2024 | THE UNIVERISTY OF TEXAS MD ANDERSON CANCER CENTER, A COMPONENT OF THE UNIVERISTY OF TEXAS SYSTEM | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | T32CA261856 | Image Guided Cancer Therapy Training Program | 000 | 3 | NIH | 3/27/2024 | $113,705 |
| | 2024 | 2024 | THE UNIVERISTY OF TEXAS MD ANDERSON CANCER CENTER, A COMPONENT OF THE UNIVERISTY OF TEXAS SYSTEM | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01NS126252 | Regulation of Peripheral Neuropathic Pain by B Cells | 000 | 3 | NIH | 3/19/2024 | $533,810 |
| | 2024 | 2024 | THE UNIVERISTY OF TEXAS MD ANDERSON CANCER CENTER, A COMPONENT OF THE UNIVERISTY OF TEXAS SYSTEM | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R61NS119642 | Relaxivity Contrast Imaging as Biomarker of Muscle Degeneration in ALS | 000 | 3 | NIH | 2/9/2024 | $582,256 |
| | 2024 | 2024 | THE UNIVERISTY OF TEXAS MD ANDERSON CANCER CENTER, A COMPONENT OF THE UNIVERISTY OF TEXAS SYSTEM | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01CA255322 | Gut Microbiome and Cancer Immunotherapy Outcomes in Advanced Renal Cell Carcinoma | 000 | 3 | NIH | 3/22/2024 | $106,370 |
| | 2024 | 2024 | THE UNIVERISTY OF TEXAS MD ANDERSON CANCER CENTER, A COMPONENT OF THE UNIVERISTY OF TEXAS SYSTEM | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01EB032533 | Enhanced Biomechanical Modeling of the Breast for Womens Health | 000 | 3 | NIH | 2/26/2024 | $576,093 |
| | 2024 | 2024 | THE UNIVERISTY OF TEXAS MD ANDERSON CANCER CENTER, A COMPONENT OF THE UNIVERISTY OF TEXAS SYSTEM | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | F31CA261121 | Estrogen receptors restrict tumor-promoting inflammation in K-ras mutant lung cancer | 000 | 3 | NIH | 2/28/2024 | $35,191 |
| | 2024 | 2024 | THE UNIVERISTY OF TEXAS MD ANDERSON CANCER CENTER, A COMPONENT OF THE UNIVERISTY OF TEXAS SYSTEM | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01CA258540 | Development of irreversible electroporation-based rational combinations to potentiate the activity of cancer immunotherapy against pancreatic ductal adenocarcinoma | 000 | 3 | NIH | 1/26/2024 | $523,198 |
| | 2024 | 2024 | THE UNIVERISTY OF TEXAS MD ANDERSON CANCER CENTER, A COMPONENT OF THE UNIVERISTY OF TEXAS SYSTEM | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01CA267856 | Improving emergency care and outcomes of immune-related adverse events: The immune-related emergency disposition index (IrEDi) | 000 | 3 | NIH | 12/12/2023 | $596,605 |
| | 2024 | 2024 | THE UNIVERISTY OF TEXAS MD ANDERSON CANCER CENTER, A COMPONENT OF THE UNIVERISTY OF TEXAS SYSTEM | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01CA258788 | A Comprehensive Clinical fMRI Software Solution to Enable Mapping of Critical Functional Networks and Cerebrovascular Reactivity in the Brain | 001 | 3 | NIH | 4/16/2024 | $19,066 |
| | 2024 | 2024 | THE UNIVERISTY OF TEXAS MD ANDERSON CANCER CENTER, A COMPONENT OF THE UNIVERISTY OF TEXAS SYSTEM | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01CA258788 | A Comprehensive Clinical fMRI Software Solution to Enable Mapping of Critical Functional Networks and Cerebrovascular Reactivity in the Brain | 000 | 3 | NIH | 1/30/2024 | $343,195 |
| | 2024 | 2024 | THE UNIVERISTY OF TEXAS MD ANDERSON CANCER CENTER, A COMPONENT OF THE UNIVERISTY OF TEXAS SYSTEM | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01CA262437 | ROLE OF SORD IN SUGAR-MEDIATED CANCER METASTASIS | 001 | 4 | NIH | 4/16/2024 | $17,194 |
| | 2024 | 2024 | THE UNIVERISTY OF TEXAS MD ANDERSON CANCER CENTER, A COMPONENT OF THE UNIVERISTY OF TEXAS SYSTEM | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01CA262437 | ROLE OF SORD IN SUGAR-MEDIATED CANCER METASTASIS | 000 | 4 | NIH | 2/9/2024 | $309,484 |
| | 2024 | 2024 | UNIVERSITY OF TEXAS M. D. ANDERSON CANCER CENTER, THE | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4000 | HARRIS | USA | R01CA264987 | Radiomic and genomic predictors of breast cancer risk | 000 | 4 | NIH | 11/22/2023 | $627,886 |
| | 2024 | 2024 | THE UNIVERISTY OF TEXAS MD ANDERSON CANCER CENTER, A COMPONENT OF THE UNIVERISTY OF TEXAS SYSTEM | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | F31NS124110 | Novel Role of Peroxisome Proliferator Activated Receptor Beta/Delta in X-Linked Adrenoleukodystrophy | 000 | 3 | NIH | 12/15/2023 | $35,188 |
| | 2024 | 2024 | THE UNIVERISTY OF TEXAS MD ANDERSON CANCER CENTER, A COMPONENT OF THE UNIVERISTY OF TEXAS SYSTEM | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01DE030104 | Targeting replication stress and homologous recombination repair mechanisms in HPV-positive and negative head and neck cancer | 000 | 4 | NIH | 4/11/2024 | $345,177 |
| | 2024 | 2024 | THE UNIVERISTY OF TEXAS MD ANDERSON CANCER CENTER, A COMPONENT OF THE UNIVERISTY OF TEXAS SYSTEM | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01NS117668 | Systematic dissection of function and mechanism of long non-coding RNAs in glioblastoma | 000 | 4 | NIH | 2/23/2024 | $364,500 |
| | 2024 | 2024 | THE UNIVERISTY OF TEXAS MD ANDERSON CANCER CENTER, A COMPONENT OF THE UNIVERISTY OF TEXAS SYSTEM | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01CA251067 | Elucidating pro-metastatic collagen modifying activities of lysyl hydroxylase 2 | 000 | 4 | NIH | 3/14/2024 | $496,628 |
| | 2024 | 2024 | THE UNIVERISTY OF TEXAS MD ANDERSON CANCER CENTER, A COMPONENT OF THE UNIVERISTY OF TEXAS SYSTEM | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01CA256848 | Determining the optimal ion and fractionation scheme for the treatment of GBM in a comprehensive human organoid model | 000 | 4 | NIH | 2/8/2024 | $423,653 |
| | 2024 | 2024 | THE UNIVERISTY OF TEXAS MD ANDERSON CANCER CENTER, A COMPONENT OF THE UNIVERISTY OF TEXAS SYSTEM | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01CA260872 | A Phase II and Biomarker Study of Dual VEGF/PD-L1 Blockade in Neoadjuvant Setting in Resectable HCC Patients | 000 | 4 | NIH | 3/1/2024 | $558,978 |
| | 2024 | 2024 | THE UNIVERISTY OF TEXAS MD ANDERSON CANCER CENTER, A COMPONENT OF THE UNIVERISTY OF TEXAS SYSTEM | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01CA278967 | CRACD-controlled cell plasticity and small cell lung cancer | 000 | 1 | NIH | 12/27/2023 | $599,733 |
| | 2024 | 2024 | THE UNIVERISTY OF TEXAS MD ANDERSON CANCER CENTER, A COMPONENT OF THE UNIVERISTY OF TEXAS SYSTEM | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R21CA288804 | A Novel Strategy of Targeting Transmembrane Protein to Improve KRAS-targeted Therapy | 000 | 1 | NIH | 2/28/2024 | $214,399 |
| | 2024 | 2024 | THE UNIVERISTY OF TEXAS MD ANDERSON CANCER CENTER, A COMPONENT OF THE UNIVERISTY OF TEXAS SYSTEM | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R21CA277152 | Preclinical studies of non-nucleoside DNMT3A/3B inhibitors | 000 | 1 | NIH | 12/26/2023 | $227,205 |
| | 2024 | 2024 | THE UNIVERISTY OF TEXAS MD ANDERSON CANCER CENTER, A COMPONENT OF THE UNIVERISTY OF TEXAS SYSTEM | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R13CA287350 | Cancer Neuroscience - An Emerging Hallmark | 000 | 1 | NIH | 2/1/2024 | $15,000 |
| | 2024 | 2024 | THE UNIVERISTY OF TEXAS MD ANDERSON CANCER CENTER, A COMPONENT OF THE UNIVERISTY OF TEXAS SYSTEM | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R25DA059907 | Supporting Tobacco-Related Ongoing Education and Research (STRONGER) Scholar Program | 000 | 1 | NIH | 3/20/2024 | $288,778 |
| | 2024 | 2024 | THE UNIVERISTY OF TEXAS MD ANDERSON CANCER CENTER, A COMPONENT OF THE UNIVERISTY OF TEXAS SYSTEM | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R03DE033550 | Probabilistic Deep Learning Cervical Lymph-Node Auto-Segmentation For Imaging-enhanced Evaluation of Extracapsular Extension Risk (PDL-CLASIFIER) | 000 | 1 | NIH | 3/19/2024 | $162,000 |
| | 2024 | 2024 | THE UNIVERISTY OF TEXAS MD ANDERSON CANCER CENTER, A COMPONENT OF THE UNIVERISTY OF TEXAS SYSTEM | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R37CA288448 | Mechanisms of Hyperprogression to Immunotherapy in SMARCB1-Deficient Renal Malignancies | 000 | 1 | NIH | 3/4/2024 | $672,300 |
| | 2024 | 2024 | THE UNIVERISTY OF TEXAS MD ANDERSON CANCER CENTER, A COMPONENT OF THE UNIVERISTY OF TEXAS SYSTEM | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R03CA289563 | Effect of SIRPalpha mismatch on the outcomes of allogeneic hematopoietic stem cell transplantation (HSCT) from an HLA matched related donor | 000 | 1 | NIH | 3/8/2024 | $81,000 |
| | 2024 | 2024 | THE UNIVERISTY OF TEXAS MD ANDERSON CANCER CENTER, A COMPONENT OF THE UNIVERISTY OF TEXAS SYSTEM | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01CA288617 | TROP2-Directed CAR-NK Cells for the Immunotherapy of Pancreatic Cancer | 000 | 1 | NIH | 4/5/2024 | $370,575 |
| | 2024 | 2024 | THE UNIVERISTY OF TEXAS MD ANDERSON CANCER CENTER, A COMPONENT OF THE UNIVERISTY OF TEXAS SYSTEM | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R21CA273661 | A novel uterine leiomyosarcoma mouse model for therapeutic development | 000 | 1 | NIH | 1/11/2024 | $227,205 |
| | 2024 | 2024 | THE UNIVERISTY OF TEXAS MD ANDERSON CANCER CENTER, A COMPONENT OF THE UNIVERISTY OF TEXAS SYSTEM | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01CA279452 | Targeting non-small cell lung cancer cells and the adverse tumor microenvironment with a small-molecule STAT3 inhibitor | 000 | 1 | NIH | 12/19/2023 | $672,297 |
| | 2024 | 2024 | THE UNIVERISTY OF TEXAS MD ANDERSON CANCER CENTER, A COMPONENT OF THE UNIVERISTY OF TEXAS SYSTEM | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01CA285980 | Use of Noninvasive Biomarkers and Advanced MRI for early detection of NF1-associated MPNSTs | 000 | 1 | NIH | 3/11/2024 | $613,597 |
| | 2024 | 2024 | THE UNIVERISTY OF TEXAS MD ANDERSON CANCER CENTER, A COMPONENT OF THE UNIVERISTY OF TEXAS SYSTEM | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01GM152497 | Computational toolkit for robust detection of genomic variation in human leukocyte antigen genes | 000 | 1 | NIH | 3/18/2024 | $307,835 |
| | 2024 | 2024 | THE UNIVERISTY OF TEXAS MD ANDERSON CANCER CENTER, A COMPONENT OF THE UNIVERISTY OF TEXAS SYSTEM | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R21CA274085 | Impact of tamoxifen treatment on neutrophils in breast cancer patients | 000 | 1 | NIH | 3/7/2024 | $191,704 |
| | 2024 | 2024 | THE UNIVERISTY OF TEXAS MD ANDERSON CANCER CENTER, A COMPONENT OF THE UNIVERISTY OF TEXAS SYSTEM | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R21AI177931 | Delineation of mechanisms underlying response regulator activation in group A Streptococcus | 000 | 1 | NIH | 1/30/2024 | $218,700 |
| | 2024 | 2024 | THE UNIVERISTY OF TEXAS MD ANDERSON CANCER CENTER, A COMPONENT OF THE UNIVERISTY OF TEXAS SYSTEM | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R21CA286318 | Exploring new strategy for breast cancer immunoprevention by targeting histamine receptor H1 | 000 | 1 | NIH | 2/14/2024 | $227,205 |
| | 2024 | 2024 | UNIVERSITY OF TEXAS M. D. ANDERSON CANCER CENTER, THE | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4000 | HARRIS | USA | K22CA279077 | Enhancing the efficacy of immunotherapy by optimal use of SMAC mimetics | 000 | 1 | NIH | 11/14/2023 | $192,240 |
| | 2024 | 2024 | THE UNIVERISTY OF TEXAS MD ANDERSON CANCER CENTER, A COMPONENT OF THE UNIVERISTY OF TEXAS SYSTEM | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01CA278938 | Comparative Effectiveness of Sequential Pharmacotherapeutic Strategies and Virtually Delivered Treatment to Optimize Smoking Cessation | 001 | 1 | NIH | 12/22/2023 | $0 |
| | 2024 | 2024 | THE UNIVERISTY OF TEXAS MD ANDERSON CANCER CENTER, A COMPONENT OF THE UNIVERISTY OF TEXAS SYSTEM | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01CA278938 | Comparative Effectiveness of Sequential Pharmacotherapeutic Strategies and Virtually Delivered Treatment to Optimize Smoking Cessation | 000 | 1 | NIH | 12/20/2023 | $923,199 |
| | 2024 | 2024 | THE UNIVERISTY OF TEXAS MD ANDERSON CANCER CENTER, A COMPONENT OF THE UNIVERISTY OF TEXAS SYSTEM | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01CA279749 | Integrating patient-reported outcomes and T-cell receptor sequencing to predict immune-related adverse events | 000 | 1 | NIH | 1/19/2024 | $657,119 |
| | 2024 | 2024 | THE UNIVERISTY OF TEXAS MD ANDERSON CANCER CENTER, A COMPONENT OF THE UNIVERISTY OF TEXAS SYSTEM | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R03CA279867 | Calcium metabolism and lung cancer preneoplasia | 000 | 1 | NIH | 1/1/2024 | $81,000 |
|
